Curebase, San Francisco, CA-based technology-driven clinical trial startup, raised $40m in Series B funding.
TheRound was led by Industry VenturesParticipation from Acrew Capital, World Innovation LabAnd Positive Sum, GaingelsGGV Capital, Bold CapitalAnd Xfund. TheThe round also included a strategic investor by a global biopharmaceutical firm Gilead Sciences.
The company, which has raised a total of $59m, intends to use the funds to continue development of its solutions.
Founded in2017 by CEO Tom Lemberg, CurebaseOffers decentralized clinical trials and patient-centric software. The company’s virtual and hybrid research sites offer patients the opportunity to participate inClinical studies can be done in any location, including community providers and home-based care. ThePlatform allows sponsors and physicians to conduct clinical research in any size practice, including independent clinics and large academic research sites.
TheCompany has completed over 50 studies, with a 300-400% increase in year-over-year growth.